BTG PLC has added Irish inferior vena cava filter firm Novate Medical Ltd. to complement its vascular device portfolio. The acquisition, announced Sept. 7, will cost $20m upfront, plus up to $130m in milestone payments.
Novate's Sentry device was 510(k)-cleared in 2017 and is the first bioconvertible IVC filter, meaning it integrates into the vessel wall over time and does not need to be retrieved....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?